Harvard Medical School news from FierceBiotech
News
Resveratrol potential fires interest in longevity drugs
Interest in longevity drugs continues to grow as new research points to the tonic effects of resveratrol. The New York Times notes that some scientists have become so enamored by the potential of the... Read more...
C&L: PDL BioPharma's L. Patrick Gage resigns
PDL BioPharma director and interim Chief Executive L. Patrick Gage resigned due to differences among the board about prioritizing company goals. Histogenics has named F. Ken Andrews president and... Read more...
FDA approves Lilly's ADHD drug Strattera
Eli Lilly has won FDA approval of Strattera, a therapy designed to treat ADHD. Lilly says this is the first regulatory win for a non-stimulant ADHD drug in a market dominated by two... Read more...
Millennium's Levin uses golden touch to fund start-up
Mark Levin earned a reputation for a colorful personality with an incredible knack for raising cash as co-founder of Millennium Pharmaceuticals. Two weeks ago, Takeda helped seal Levin's reputation... Read more...
ALSO NOTED: NMT closes trial; NovaMed raises cash; Sinovac sells shares; Genentech team advances lupus work; and much more...
> NMT Medical says it will close a trial of its migraine technology after experiencing difficulties--and high costs--enrolling patients. Read more...
RNAi screening finds 273 proteins used by HIV
Harvard Medical School's Dr. Stephen J. Elledge and a team of scientists used RNA interference to screen thousands of protein-making genes, and have identified 273 proteins HIV needs in order to... Read more...
ALSO NOTED: Nuvelo drug gets fast tracked; QLT brings on Goldman Sachs; and much more...
> Sanofi-Aventis has set up a small executive committee to set strategy, allocate resources and oversee company management, according to anonymous sources who talked to APM Europe. The idea is to... Read more...
Merck, Harvard forge research agreement
Merck and Harvard Medical School have signed an agreement to jointly advance research programs in two core areas--oncology and central nervous system disorders. Financial details were not disclosed.... Read more...
Get more Harvard Medical School coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
